Lynparza is paving new ground in pancreatic cancer, aiming to establish a maintenance setting and patient segmentation based on a biomarker (gBRCA mt) in first-line metastatic disease.
Day three of ASCO 2019 saw a showdown between two anti-CD38 compounds in multiple myeloma, Janssen's Darzalex and Sanofi's isatuximab. Darzalex showed more positive data in newly-d
Exclusive live coverage from day four of the American Society of Clinical Oncology's annual meeting in Chicago. • To view all of our coverage from the preeminent cancer event, prod
Exclusive live coverage from day three of the American Society of Clinical Oncology's annual meeting in Chicago. • To view all of our coverage from the preeminent cancer event, pro
Exclusive live coverage from day two of the American Society of Clinical Oncology's annual meeting in Chicago. • To view all of our coverage from the preeminent cancer event, produ